Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2024-10-03 Declaration of Voting R…
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed submission of voting results from the 30th Annual General Meeting (AGM) of Lincoln Pharmaceuticals Limited, including the Scrutinizer's Report on remote e-voting and e-voting at the AGM. It references Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs voting results disclosures. The content includes detailed voting percentages, resolutions passed, and the Scrutinizer's certification of the voting process. There is no financial data or management discussion, nor is it a report publication announcement. The document is clearly focused on the official declaration of voting results from the AGM, which fits the category of "Declaration of Voting Results & Voting Rights Announcements (DVA)".
2024-10-03 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is a detailed description of the proceedings of the 30th Annual General Meeting (AGM) of Lincoln Pharmaceuticals Limited held on September 30, 2024. It includes information about the meeting format (video conferencing), quorum, voting procedures, introduction of directors and auditors, and the resolutions proposed and approved during the meeting. The document does not contain the full financial statements or detailed financial analysis but rather summarizes the meeting events and resolutions. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM. The document length (7422 characters) and content confirm it is not merely an announcement but a substantive report of the AGM proceedings.
2024-09-30 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) informing about the closure of the trading window pursuant to SEBI regulations ahead of the announcement of quarterly financial results for the quarter ended September 30, 2024. It does not contain any financial data or results itself, nor does it present a report. It is an announcement related to compliance and trading restrictions before financial results are declared. The document length is short (2497 characters) and it serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-23 English
Copy of Newspaper Publication
AGM Information Classification · 95% confidence The document is a detailed notice regarding the 30th Annual General Meeting (AGM) of the company, including information about the meeting date, mode (Video Conferencing/Other Audio Visual Means), book closure dates, e-voting instructions, and dividend information. It references the Notice of the AGM and the Annual Report for the year ended March 31, 2024, but does not contain the full Annual Report or financial statements itself. The document is primarily an announcement and instructions related to the AGM and voting process, not the report itself. Therefore, it fits the category of AGM Information (AGM-R). The document length is substantial (15,000 characters), but the content is focused on the AGM notice and related procedural information rather than the full annual report or financial data.
2024-09-07 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is a detailed notice for the 30th Annual General Meeting (AGM) of Lincoln Pharmaceuticals Limited. It includes the agenda items such as adoption of audited financial statements for the year ended March 31, 2024, declaration of dividend, appointment/re-appointment of directors, and ratification of cost auditor remuneration. It also contains procedural notes about the AGM, voting, and regulatory compliance references (MCA and SEBI circulars). The document is clearly a notice and agenda for the AGM, not the actual annual report or financial statements themselves. It is lengthy (15,000 characters) and contains detailed information about the meeting but does not contain the full financial report or audit report. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including notices and agendas.
2024-09-06 English
Book Closure
Notice of Dividend Amount Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the book closure dates for the purpose of determining entitlement to a final dividend for the financial year ending March 31, 2024. It mentions the upcoming 30th Annual General Meeting scheduled for September 30, 2024, and provides details about the dividend percentage and payment conditions. The document is short (3092 characters) and serves as an announcement of the book closure and dividend details rather than a full financial report or detailed dividend report. It does not contain financial statements or detailed analysis but is a formal notification to the exchanges and shareholders. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and related shareholder information.
2024-08-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.